Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Clear cell mesotheliomas with inactivating VHL mutations and near-haploid genomic features

M. Michal, O. Kravtsov, JS. Ross, D. Skanderová, P. Martínek, E. Mosaieby, DA. Mata, EA. Williams, YP. Hung

. 2023 ; 62 (5) : 267-274. [pub] 20221225

Language English Country United States

Document type Systematic Review, Journal Article

Clear cell mesothelioma is uncommon and shows predominance of clear cells with resemblance to clear cell carcinomas. Clinicopathologic and molecular descriptions of clear cell mesothelioma remained limited. In this study, we identified an index patient with clear cell mesothelioma, confirmed by immunohistochemical and ultrastructural studies. Targeted next-generation sequencing revealed the presence of an inactivating VHL mutation. We then systematically searched for VHL-mutant mesotheliomas in a comprehensive genomic profiling database of 1532 mesotheliomas. Collectively, we identified a cohort of four VHL-mutant clear cell mesotheliomas, including three peritoneal and one pleural tumors from three females and one male, with age range of 47-68 (median 63) years. Histologically, each tumor showed a microcystic to tubulopapillary architecture with prominent clear cells. By next-generation DNA sequencing, each of the four clear cell mesotheliomas harbored inactivating VHL mutations, while lacking other alterations typical of mesotheliomas such as BAP1, NF2, SETD2, CDKN2A, CDKN2B, TP53, and PTEN. By using low-pass whole genome sequencing on the index case and targeted next-generation sequencing on the remaining three cases, we identified extensive loss of heterozygosity throughout the genome but consistently sparing chromosomes 5, 7, and 20, characteristic of genomic near-haploidization. In summary, clear cell mesotheliomas were characterized by inactivating VHL mutations and genomic near-haploidization and appeared to represent a distinct clinicopathologic and molecular category of mesotheliomas. Our findings implicate VHL in the pathogenesis of a subset of mesotheliomas, particularly those with clear cell morphology.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003615
003      
CZ-PrNML
005      
20230425140747.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/gcc.23119 $2 doi
035    __
$a (PubMed)36515470
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Michal, Michael $u Department of Pathology, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic $u Department of Pathology, Bioptical Laboratory Ltd., Plzen, Czech Republic $1 https://orcid.org/0000000344037027
245    10
$a Clear cell mesotheliomas with inactivating VHL mutations and near-haploid genomic features / $c M. Michal, O. Kravtsov, JS. Ross, D. Skanderová, P. Martínek, E. Mosaieby, DA. Mata, EA. Williams, YP. Hung
520    9_
$a Clear cell mesothelioma is uncommon and shows predominance of clear cells with resemblance to clear cell carcinomas. Clinicopathologic and molecular descriptions of clear cell mesothelioma remained limited. In this study, we identified an index patient with clear cell mesothelioma, confirmed by immunohistochemical and ultrastructural studies. Targeted next-generation sequencing revealed the presence of an inactivating VHL mutation. We then systematically searched for VHL-mutant mesotheliomas in a comprehensive genomic profiling database of 1532 mesotheliomas. Collectively, we identified a cohort of four VHL-mutant clear cell mesotheliomas, including three peritoneal and one pleural tumors from three females and one male, with age range of 47-68 (median 63) years. Histologically, each tumor showed a microcystic to tubulopapillary architecture with prominent clear cells. By next-generation DNA sequencing, each of the four clear cell mesotheliomas harbored inactivating VHL mutations, while lacking other alterations typical of mesotheliomas such as BAP1, NF2, SETD2, CDKN2A, CDKN2B, TP53, and PTEN. By using low-pass whole genome sequencing on the index case and targeted next-generation sequencing on the remaining three cases, we identified extensive loss of heterozygosity throughout the genome but consistently sparing chromosomes 5, 7, and 20, characteristic of genomic near-haploidization. In summary, clear cell mesotheliomas were characterized by inactivating VHL mutations and genomic near-haploidization and appeared to represent a distinct clinicopathologic and molecular category of mesotheliomas. Our findings implicate VHL in the pathogenesis of a subset of mesotheliomas, particularly those with clear cell morphology.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a haploidie $7 D006238
650    12
$a nádory plic $x genetika $7 D008175
650    12
$a mezoteliom $x genetika $7 D008654
650    12
$a maligní mezoteliom $7 D000086002
650    _2
$a mutace $7 D009154
650    _2
$a chromozomální aberace $7 D002869
650    _2
$a genomika $7 D023281
650    _2
$a thiolesterasa ubikvitinu $x genetika $7 D043222
650    _2
$a nádorový supresorový protein VHL $x genetika $7 D051794
655    _2
$a systematický přehled $7 D000078182
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kravtsov, Oleksandr $u Department of Pathology, State University of New York Upstate Medical University, New York, New York, USA $1 https://orcid.org/0000000209971933
700    1_
$a Ross, Jeffrey S $u Department of Pathology, State University of New York Upstate Medical University, New York, New York, USA $u Department of Pathology, Foundation Medicine, Inc., Cambridge, Massachusetts, USA
700    1_
$a Skanderová, Daniela $u Department of Clinical and Molecular Pathology, Institute of Translational and Molecular Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Martínek, Petr $u Department of Pathology, Bioptical Laboratory Ltd., Plzen, Czech Republic
700    1_
$a Mosaieby, Elaheh $u Department of Pathology, Bioptical Laboratory Ltd., Plzen, Czech Republic
700    1_
$a Mata, Douglas A $u Department of Pathology, Foundation Medicine, Inc., Cambridge, Massachusetts, USA $1 https://orcid.org/0000000280598668
700    1_
$a Williams, Erik A $u Department of Pathology, Foundation Medicine, Inc., Cambridge, Massachusetts, USA $u Department of Pathology and Laboratory Medicine, Sylvester Comprehensive Cancer Center, and Jackson Memorial Hospitals, University of Miami, Miami, Florida, USA
700    1_
$a Hung, Yin P $u Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA $1 https://orcid.org/0000000285681591
773    0_
$w MED00001898 $t Genes, chromosomes & cancer $x 1098-2264 $g Roč. 62, č. 5 (2023), s. 267-274
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36515470 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425140743 $b ABA008
999    __
$a ok $b bmc $g 1924349 $s 1189824
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 62 $c 5 $d 267-274 $e 20221225 $i 1098-2264 $m Genes, chromosomes & cancer $n Genes Chromosom Cancer $x MED00001898
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...